Asset
VUTRISIRAN SODIUM
Alnylam Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02797847 | phase1 | completed | 2016-06-07 | 2018-01-12 | Alnylam Pharmaceuticals | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 215515 | NDA | ALNYLAM PHARMACEUTICALS INC |
Marketed products (1)
- AMVUTTRA